Streptococcus suis serotype 9 bacterin immunogenicity and protective efficacy

Büttner, Nadine; Beineke, Andreas; Buhr, Nicole de; Lilienthal, Sabrina; Merkel, Jörg; Waldmann, Karl-Heinz; Valentin‐Weigand, Peter; Baums, Christoph Georg

doi:10.1016/j.vetimm.2012.03.012

Cited by 29 publications

(37 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, at birth all antibody-expressing B cells are IgM ϩ in pigs, in contrast to other species (17,43,44 Identification of the protease cleaving IgM bound to the bacterial surface should help to improve vaccines against S. suis. Induction of opsonizing antibodies is crucial for the protective efficacy of an S. suis bacterin (27,45). As complement is important for the immunoglobulin-mediated killing elicited by an S. suis bacterin (unpublished results) and Ide Ssuis promoted survival in blood of a vaccinated piglet, we hypothesize that neutralization of the Ide Ssuis IgM protease activity might substantially improve the protective efficacy of bacterins or other future vaccines inducing opsonizing antibodies.…”

Section: Discussionmentioning

confidence: 90%

Identification of a Novel Host-Specific IgM Protease in Streptococcus suis

Seele

Singpiel

Spoerry

et al. 2012

Journal of Bacteriology

View full text Add to dashboard Cite

bStreptococcus suis serotype 2 is a highly invasive, extracellular pathogen in pigs with the capacity to cause severe infections in humans. This study was initiated by the finding that IgM degradation products are released after opsonization of S. suis. The objective of this work was to identify the bacterial factor responsible for IgM degradation. The results of this study showed that a member of the IdeS family, designated Ide Ssuis (Immunoglobulin M-degrading enzyme of S. suis), is responsible and sufficient for IgM cleavage. Recombinant Ide Ssuis was found to degrade only IgM but neither IgG nor IgA. Interestingly, Western blot analysis revealed that Ide Ssuis is host specific, as it exclusively cleaves porcine IgM but not IgM from six other species, including a closely related member of the Suidae family. As demonstrated by flow cytometry and immunofluorescence microscopy, Ide Ssuis modulates binding of IgM to the bacterial surface. Ide Ssuis is the first prokaryotic IgM-specific protease described, indicating that this enzyme is involved in a so-far-unknown mechanism of host-pathogen interaction at an early stage of the host immune response. Furthermore, cleavage of porcine IgM by Ide Ssuis is the first identified phenotype reflecting functional adaptation of S. suis to pigs as the main host.

show abstract

Section: Discussionmentioning

confidence: 90%

Identification of a Novel Host-Specific IgM Protease in Streptococcus suis

Seele

Singpiel

Spoerry

et al. 2012

Journal of Bacteriology

View full text Add to dashboard Cite

show abstract

“…This is mainly because we have observed many piglets with high titers against MRP, SAO and suilysin being highly susceptible to a challenge with S. suis [10,11,20]. Thus, we assumed that vaccination with the IgM protease Ide Ssuis might, at its best, improve the protective efficacy of a bacterin by eliciting protection after priming.…”

Section: Discussionmentioning

confidence: 99%

“…All surviving piglets were sacrificed 14 days post infection (dpi). After euthanasia every animal went through the same procedure of necropsy to collect the following samples for histological (h) and semi-quantitative bacteriological (b) investigations as described previously [10,19,20]: cerebrospinal fluid (b); brain (b, h); tarsal and carpal joints (b, h), peritoneal, pleural and pericardial swabs (b), peritoneum, pleura and pericardium (h); cranial lobe of the left lung (b, h); liver (b, h); spleen (b, h); bicuspidalis (b, h) and tonsil (b, h). The histological screenings were scored as described [19] and briefly mentioned in the footnotes of Table 2.…”

Section: Animal Experimentsmentioning

confidence: 99%

The immunoglobulin M-degrading enzyme of Streptococcus suis , Ide Ssuis , is a highly protective antigen against serotype 2

Seele¹,

Hillermann²,

Beineke³

et al. 2015

Vaccine

Self Cite

View full text Add to dashboard Cite

“…Based on the sequence of seven house-keeping genes ( cpn60 , dpr , recA , aroA , thrA , gki , and mutS ), S. suis could be classified into 1003 STs. Although a serotype 9 strain has been demonstrated to give cross-protection against different STs belonging to CC16 (43), there is no live vaccine reported that provides cross-protection against different STs in CC1, which is considered the most virulent and extensive clonal complex (5). In this study, three STs belonging to CC1 were used: ST1 predominates in many European and Asian countries while ST7 is considered to be responsible for two outbreaks in China (5).…”

Section: Resultsmentioning

confidence: 99%

A capsular polysaccharide-expressing live vaccine suppresses streptococcal toxic shock-like syndrome and provides sequence type-independent protection during Streptococcus suis infection

Chang

et al. 2018

Preprint

View full text Add to dashboard Cite

12Streptococcus suis (S. suis) is an encapsulated zoonotic pathogen, which is responsible for 13 bacterial meningitis and streptococcal toxic shock-like syndrome (STSLS). Despite many 14 attempts to develop an effective vaccine, none is currently available. Here, a capsular 15 polysaccharide (CPS)-expressing attenuated mutant 2015033 was constructed by deleting 16 five virulence-associated factors (sly, scpA, ssnA, fhb, and ssads) in an outbreak S. suis strain 17 SC19. Genes mentioned above are associated with either innate immunity-evading or tissue 18 barrier-invading. Deletion of these genes did not impact the growth ability and CPS 19 generation of 2015033, and the mutant exhibited no hemolytic activity to erythrocytes and no 20 cytotoxicity to different epithelial or endothelial cells. In addition, 2015033 was more easily 21 2 eliminated by whole human blood in vitro and by mouse blood in vivo. In addition, 2015033 22 showed a diminished invasive ability in different mouse organs (brain, lung, and liver) and 23 avirulent properties in mice associated with weak inflammation-inducing ability. 24Immunization with 2015033 triggered T cell-dependent immunity and this immunity 25 suppressed STSLS during SC19 infection by inhibiting excessive proinflammatory responses. 26In addition, immunization with 2015033 successfully conferred sequence type 27 (STs)-independent protection to mice during heterogeneous infections (ST1, ST7, and ST658). 28This study presents the feasibility of the strategy of multi-gene deletion for the development 29 of promising live vaccines against invasive encapsulated pathogens. 30 IMPORTANCE 31 S. suis is a traditional zoonotic agent causing human meningitis and STSLS, which is also a 32 neglected emerging food-borne pathogen. Increasing antimicrobial resistance invokes 33 reduction of preventative use of antibiotics in livestock creating an urgent need for effective 34 vaccines. Given the expression of CPS is the basis for promising vaccines against 35 encapsulated pathogens, and in order to find an effective and economical strategy for 36 CPS-based vaccine development, multi-gene deletion was introduced into the design of a S. 37 suis vaccine for the first time. From our results, CPS-expressing attenuated mutant 2015033 38 exhibited diminished evasive ability against the innate immune system and reduced invasive 39 properties against different host barriers. To our knowledge, 2015033 is the first 40 STSLS-suppressing S. suis vaccine to provide STs-independent protection during 41 heterogeneous infections. 42Streptococcus suis (S. suis) is an important zoonotic pathogen with considerably high 44 phenotypic heterogeneity, which can be classified into 33 serotypes based on the antigenicity 45 of their capsular polysaccharides (CPS) (1) and 1003 sequence types (STs) according to the 46 sequence of seven house-keeping genes (cpn60, dpr, recA, aroA, thrA, gki, and mutS) (2). As 47 the most virulent serotype, S. suis serotype 2 (S. suis 2) has caused a wide variety of diseases 48 in pigs, incl...

show abstract

Streptococcus suis serotype 9 bacterin immunogenicity and protective efficacy

Cited by 29 publications

References 26 publications

Identification of a Novel Host-Specific IgM Protease in Streptococcus suis

Identification of a Novel Host-Specific IgM Protease in Streptococcus suis

The immunoglobulin M-degrading enzyme of Streptococcus suis , Ide Ssuis , is a highly protective antigen against serotype 2

A capsular polysaccharide-expressing live vaccine suppresses streptococcal toxic shock-like syndrome and provides sequence type-independent protection during Streptococcus suis infection

Contact Info

Product

Resources

About